1. Home
  2. VYX vs ANAB Comparison

VYX vs ANAB Comparison

Compare VYX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$11.03

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$44.69

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYX
ANAB
Founded
1881
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
VYX
ANAB
Price
$11.03
$44.69
Analyst Decision
Buy
Buy
Analyst Count
6
12
Target Price
$15.17
$58.09
AVG Volume (30 Days)
1.6M
501.4K
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,653,000,000.00
$169,467,000.00
Revenue This Year
N/A
$135.45
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
196.42
52 Week Low
$7.55
$12.21
52 Week High
$14.67
$52.47

Technical Indicators

Market Signals
Indicator
VYX
ANAB
Relative Strength Index (RSI) 61.61 49.32
Support Level $10.15 $42.00
Resistance Level $10.62 $47.36
Average True Range (ATR) 0.36 2.46
MACD 0.08 -0.90
Stochastic Oscillator 99.20 26.41

Price Performance

Historical Comparison
VYX
ANAB

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: